Guest editorial: The placebo enigma in antidepressant clinical trials

Journal of Clinical Psychopharmacology

Volumn 21, Issue 2, 2001, Pages 123-125

  Khan, Arif ^a,b   Brown, Walter A ^c,d  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ANXIETY NEUROSIS; CHRONICITY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; EDITORIAL; ELECTROCONVULSIVE THERAPY; HUMAN; INSOMNIA; PANIC; PRIORITY JOURNAL; PSYCHOTHERAPY; RATING SCALE; REMISSION; SIGNAL NOISE RATIO; METHODOLOGY; NOTE; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; PLACEBO EFFECT;

EID: 0035103395     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200104000-00001     Document Type: Editorial

References (6)

1. Patient and rater education of expectations in clinical trials (PREECT)
2. Which depressed patients should receive antidepressants?
3. Severity of depression and response to antidepressants and placebo: An analysis of the FDA database
4. The DST as a predictor of outcome in depression: A meta-analysis
5. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?